The Administrative Core will be the 'central nervous system' of the proposed OklahomaRheumatic Disease Research Core Center, functioning as the governing center, the feasibilityproject selection and project monitoring center, the mentoring center, the scientific core oversightcenter, the Enrichment series leadership and the checkpoint of the success of the Center as awhole. The Administrative Core will consist of the Director, Associate Director, the Senior AdvisoryCommittee, the External Advisory Committee and the Core Administrator. The Senior AdvisoryCommittee meetings will be held under the auspices of the Administrative Core, and the decisionsof the Senior Advisory Committee will be implemented by this Core. The Administrative Core willalso help facilitate interdisciplinary interactions between Core Investigators and assist withfeasibility project selection and mentoring. After submission by approved appropriate investigators,feasibility applications will be reviewed first by the Senior Advisory Committee and then selectprojects evaluated by an External Advisory Committee of Gary Gilkeson, MD, John Mulvihill MD,PhD, Jill Morris, MPH, PhD, Carl Langfeld, PhD, and Edward Wakeland, PhD. After provision ofNIH-style reviews, the Senior and External Advisory Committees will meet with applicants formentoring sessions. This Core will assist feasibility project by helping with the administrative dutiesassociated with research projects (i.e., grants management, human subject training, IRB applicationand patient sample compliance, IACUC application and compliance, grant and manuscriptpreparations, presentations, travel arrangements, budget management, and personnel recruitmentand retention). This revised core will provide financial oversight of the Cores and FeasibilityProjects. The Administrative Core will also coordinate and implement the Enrichment programconsisting of key meetings, seminars, important scientific visitors, and mentoring sessions. TheAdministrative Core will be instrumental in the Center's goal of interaction of multi-disciplinedinvestigators in the pursuit of understanding the etiology and pathogenesis of rheumatic diseasesand will also be responsible for the evaluation of the success of the Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
1P30AR053483-01A1
Application #
7325050
Study Section
Special Emphasis Panel (ZAR1-KM-K (M1))
Project Start
2007-09-01
Project End
2012-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$197,284
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531
Jog, Neelakshi R; Chakravarty, Eliza F; Guthridge, Joel M et al. (2018) Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Front Immunol 9:2198
Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824
Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :
Scofield, R Hal; Sharma, Rohan; Harris, Valerie M (2018) Reply. Arthritis Rheumatol 70:626-627
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480
Martínez-Bueno, Manuel; Oparina, Nina; Dozmorov, Mikhail G et al. (2018) Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci 19:
Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113

Showing the most recent 10 out of 284 publications